Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-304 ...

Azenta (AZTA -17.77%), a provider of life sciences solutions focusing on sample management and genomics services, released its third-quarter fiscal 2025 results on August 5, 2025. The headline: Non-GAAP profitability beat expectations, but GAAP revenue was flat and missed analyst forecasts. Azenta posted non-GAAP diluted EPS from continuing operations of $0.19, outperforming the $0.14 consensus Non-GAAP EPS estimate. Revenue (GAAP) was $144 million, essentially unchanged from a year earlier and $5.38 millio ...

Azenta (AZTA) Q3 2025 Earnings Call August 05, 2025 08:30 AM ET Speaker0Greetings, and welcome to the Centa Q3 twenty twenty five Financial Results. During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question and answer session. At that time, if you have a question, please press the star followed by one on your telephone. As a reminder, this conference is being recorded Tuesday, 08/05/2025.I will now like to turn the conference over to Yvonne Perron, Vice ...

The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. | | | | | | | Quarter Ended | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Dollars in millions, except per share data | June 30, | | | March 31, | | June 30, | Change | | | | 2025 | | | 2025 | | 2024 | Prior Qtr | Prior Yr. | | Revenue from Continuing Operations $ | | 144 | $ | ...

BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data June 30, March 31, June 30, Change 2025 202 ...

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnosticsBAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clin ...

BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens.The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.azenta.com/events. A replay w ...

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy developme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-30 ...

Azenta (AZTA) Q2 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Yvonne Perron - VP - Financial Planning & Analysis and Investor RelationsJohn Marotta - President & CEOLawrence Lin - Executive VP & CFOVijay Kumar - Senior Managing DirectorPaul Knight - Managing Director Conference Call Participants David Saxon - Senior AnalystMatthew Stanton - AnalystBrendan Smith - Director & Senior Analyst Operator Greetings and welcome to the Azenta Q2 twenty twenty five Financial Results. During the pre ...